StockData

Iovance Biotherapeutics vs Krystal Biotech

IOVA and KRYS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IOVA and KRYS compare

Krystal Biotech is the larger company, worth 2.6 times as much as Iovance Biotherapeutics ($8.8B against $3.4B).

Iovance Biotherapeutics grew revenue faster over the last twelve months (34.5% versus 22.6% for Krystal Biotech).

Krystal Biotech keeps more of each dollar of sales as profit, with a net margin of 54.8% compared with −89.1% at Iovance Biotherapeutics.

Krystal Biotech scores higher on the StockData Score (11 against 9 for Iovance Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIOVAKRYS
Size and price
Market cap$3.4B$8.8B
Share price$7.53$298.55
Change, 1 year205%44.8%
Change, 5 years−59.3%650%
Beta (5Y)1.451.01
Employees975295
StockData Score
Total score911 (better)
Valuation score01 (better)
Growth score2 (better)1
Performance score13 (better)
Health score66
Dividend score00
Valuation
P/E–37.4×
P/S10.5× (better)20.1×
P/B4.6× (better)6.5×
EV/EBITDA–40.4×
P/FCF–34.3×
FCF yield−8.7%2.9% (better)
Fair value$4.03$195.99
Margin of safety−86.8%−52.3% (better)
Growth
Revenue growth (TTM)34.5% (better)22.6%
Net income growth (TTM)–64.6%
EPS growth (TTM)–62.2%
Profitability
Gross margin48.4%–
Operating margin−92.7%44.9% (better)
Net margin−89.1%54.8% (better)
FCF margin−91.2%58.5% (better)
Return on equity−40.4%20.1% (better)
Return on invested capital−57.0%45.3% (better)
Financial health
Debt / equity0.000.00
Current ratio4.358.32 (better)
Altman Z-score6.7039.06 (better)
Piotroski F-score46 (better)
Dividends and buybacks
Buyback yield−8.6%–
Shareholder yield−8.6%0.00% (better)
Ownership
Held by institutions63.3%102%
Held by insiders0.39%17.1%
Insider net buying, 12 months–−$105M
Short interest, % of float14.4%12.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.